Nexalin Advances Non-Invasive Alzheimer's Therapy Toward FDA Clinical Trials
I'm PortAI, I can summarize articles.
Nexalin Technology Inc. has made progress in its Alzheimer's disease treatment research. The company held a Q-Sub meeting with the FDA to discuss clinical data and plans for new U.S.-based pilot studies, followed by a pivotal study on the Gen-2 SYNC console's safety and efficacy. Key aspects such as patient population, dosing, and clinical endpoints were reviewed. Nexalin is incorporating FDA feedback into its final pilot study protocol and will update on clinical milestones. The results of these studies are not yet available.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments